Dyslipidemia and its Treatment in HIV Infection.

摘要: HIV-infected patients have metabolic abnormalities that put them at increased risk of cardiovascular disease (CVD), including associated with HIV infection itself, antiretroviral treatment, restoration to health, and body composition changes. The 2 major components dyslipidemia in are hypertriglyceridemia reduction high-density lipoprotein (HDL) cholesterol (with likely altered function HDL cholesterol); these contribute atherosclerotic risk. Adverse effects drugs on lipids not class specific but rather particular drugs. Thus, practitioners need be cognizant the risks posed by individual increases CVD independent traditional factors. relative has decreased recent years increasing use lipid-lowering therapy. However, therapy is complicated numerous potential drug interactions consider when prescribing This article summarizes a presentation made Carl Grunfeld, MD, PhD, International AIDS Society-USA continuing medical education program Los Angeles March 2010. original available as Webcast www.iasusa.org.